Email updates

Keep up to date with the latest news and content from Nutrition Journal and BioMed Central.

Open Access Highly Accessed Research

Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial

Bor-Jen Lee1, Yu-Fen Tseng2, Chi-Hua Yen345 and Ping-Ting Lin26*

Author Affiliations

1 The Intensive Care Unit, Taichung Veterans General Hospital, Taichung 40705, Taiwan

2 School of Nutrition, Chung Shan Medical University, Taichung 40201, Taiwan

3 Department of Family and Community Medicine, Chung Shan Medical University Hospital, Taichung 40201, Taiwan

4 School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan

5 Center for Education and Research on Geriatrics and Gerontology, Chung Shan Medical University, Taichung 40201, Taiwan

6 Department of Nutrition, Chung Shan Medical University Hospital, Taichung 40201, Taiwan

For all author emails, please log on.

Nutrition Journal 2013, 12:142  doi:10.1186/1475-2891-12-142

Published: 6 November 2013

Abstract

Background

High oxidative stress and chronic inflammation can contribute to the pathogenesis of coronary artery disease (CAD). Coenzyme Q10 is an endogenous lipid-soluble antioxidant. Statins therapy can reduce the biosynthesis of coenzyme Q10. The purpose of this study was to investigate the effects of a coenzyme Q10 supplement (300 mg/d; 150 mg/b.i.d) on antioxidation and anti-inflammation in patients who have CAD during statins therapy.

Methods

Patients who were identified by cardiac catheterization as having at least 50% stenosis of one major coronary artery and who were treated with statins for at least one month were enrolled in this study. The subjects (n = 51) were randomly assigned to the placebo (n = 24) and coenzyme Q10 groups (Q10-300 group, n = 27). The intervention was administered for 12 weeks. The concentrations of coenzyme Q10, vitamin E, antioxidant enzymes activities (superoxide dismutase, catalase, and glutathione peroxidase), and inflammatory markers [C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6)] were measured in the 42 subjects (placebo, n = 19; Q10-300, n = 23) who completed the study.

Results

The levels of the plasma coenzyme Q10 (P < 0.001) and antioxidant enzymes activities (P < 0.05) were significantly higher after coenzyme Q10 supplementation. The levels of inflammatory markers (TNF-α, P = 0.039) were significantly lower after coenzyme Q10 supplementation. The subjects in the Q10-300 group had significantly higher vitamin E (P = 0.043) and the antioxidant enzymes activities (P < 0.05) than the placebo group at week 12. The level of plasma coenzyme Q10 was significantly positively correlated with vitamin E (P = 0.008) and antioxidant enzymes activities (P < 0.05) and was negatively correlated with TNF-α (P = 0.034) and IL-6 (P = 0.027) after coenzyme Q10 supplementation.

Conclusion

Coenzyme Q10 supplementation at 300 mg/d significantly enhances antioxidant enzymes activities and lowers inflammation in patients who have CAD during statins therapy.

Trial registration

Clinical Trials.gov Identifier: NCT01424761.

Keywords:
Coenzyme Q10; Statins; Antioxidation; Inflammation; Coronary artery disease